Uwe Klein is responsible for all aspects of Numerate’s experimental biology strategy. He has over 19 years of experience in drug discovery, coming from Theravance Biopharma, where he last held the position of Senior Director in Molecular & Cellular Biology, leading two cardiovascular programs and directing a group of biologists in research across different therapeutic areas. Uwe is author on 16 publications and 1 book chapter, and has served as an expert advisor to the European Union’s Seventh Framework Programme for Research. Uwe completed a postdoctoral fellowship at the University of California, San Francisco and at Stanford University, and holds a Certificate in Bioinformatics from the University of California, Santa Cruz. He received a M.S. in Chemistry and a Ph.D. in Biochemistry from the Goethe University in Frankfurt/Germany, with his thesis work conducted at the Max-Planck-Institute for Biophysics.